Gene · 962
Papers3,378
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
601 to 620 of 3,378
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A Novel Prognostic Prediction Model Based on Pyroptosis-Related Clusters for Breast Cancer. | J Pers Med | 2022 | 36675729 | PubTator, text mining | PubMed |
| Discovery and Validation of a SIT1-Related Prognostic Signature Associated with Immune Infiltration in Cutaneous Melanoma. | J Pers Med | 2022 | 36675674 | PubTator, text mining | PubMed |
| The Role of Alternative Splicing Factors, DDB2-Related Ageing and DNA Damage Repair in the Progression and Prognosis of Stomach Adenocarcinoma Patients. | Genes (Basel) | 2022 | 36672781 | PubTator, text mining | PubMed |
| Identification of a Novel N7-Methylguanosine-Related LncRNA Signature Predicts the Prognosis of Hepatocellular Carcinoma and Experiment Verification. | Curr Oncol | 2022 | 36661684 | PubTator, text mining | PubMed |
| New Insights into Risk Genes and Their Candidates in Multiple Sclerosis. | Neurol Int | 2022 | 36648967 | PubTator, text mining | PubMed |
| Construction and Validation of a Novel Immune Checkpoint-Related Model in Clear Cell Renal Cell Carcinoma. | Dis Markers | 2022 | 36618968 | PubTator, text mining | PubMed |
| Coiled-Coil Domain-Containing Protein 45 Is a Potential Prognostic Biomarker and Is Associated with Immune Cell Enrichment of Hepatocellular Carcinoma. | Dis Markers | 2022 | 36618966 | PubTator, text mining | PubMed |
| Prognostic and Immunological Implications of FAM72A in Pan-Cancer and Functional Validations. | Int J Mol Sci | 2022 | 36613817 | PubTator, text mining | PubMed |
| Pan-Cancer Landscape of NEIL3 in Tumor Microenvironment: A Promising Predictor for Chemotherapy and Immunotherapy. | Cancers (Basel) | 2022 | 36612106 | PubTator, text mining | PubMed |
| Microenvironmental Factors in Oral Cavity Squamous Cell Carcinoma Undergoing Surgery: Correlation with Diffusion Kurtosis Imaging and Dynamic Contrast-Enhanced MRI. | Cancers (Basel) | 2022 | 36612011 | PubTator, text mining | PubMed |
| Chromobox Family Proteins as Putative Biomarkers for Breast Cancer Management: A Preliminary Study Based on Bioinformatics Analysis and qRT-PCR Validation. | Breast Cancer (Dove Med Press) | 2022 | 36605919 | PubTator, text mining | PubMed |
| Immune activation of characteristic gut mycobiota Kazachstania pintolopesii on IL-23/IL-17R signaling in ankylosing spondylitis. | Front Cell Infect Microbiol | 2022 | 36605130 | PubTator, text mining | PubMed |
| Integrated bioinformatics analysis of IFITM1 as a prognostic biomarker and investigation of its immunological role in prostate adenocarcinoma. | Front Oncol | 2022 | 36591519 | PubTator, text mining | PubMed |
| T cell repertoire profiling in allografts and native tissues in recipients with COVID-19 after solid organ transplantation: Insight into T cell-mediated allograft protection from viral infection. | Front Immunol | 2022 | 36591281 | PubTator, text mining | PubMed |
| A culture platform to study quiescent hematopoietic stem cells following genome editing. | Cell Rep Methods | 2022 | 36590688 | PubTator, text mining | PubMed |
| A new thinking: deciphering the aberrance and clinical implication of copper-death signatures in clear cell renal cell carcinoma. | Cell Biosci | 2022 | 36581992 | PubTator, text mining | PubMed |
| Bioinformatics analyses for the identification of tumor antigens and immune subtypes of gastric adenocarcinoma. | Front Genet | 2022 | 36579327 | PubTator, text mining | PubMed |
| Genetic engineering of pigs for xenotransplantation to overcome immune rejection and physiological incompatibilities: The first clinical steps. | Front Immunol | 2022 | 36561750 | PubTator, text mining | PubMed |
| A novel necroptosis-related lncRNA based signature predicts prognosis and response to treatment in cervical cancer. | Front Genet | 2022 | 36561319 | PubTator, text mining | PubMed |
| Identification of hub genes correlated with tumor-associated M1-like macrophage infiltration in soft tissue sarcomas. | Front Genet | 2022 | 36561315 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/962/papers?page=31